Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Curr Opin Genet Dev. 2012 Feb;22(1):50-5. doi: 10.1016/j.gde.2012.02.008. Epub 2012 Mar 6.
For many years cancer research has focused on genetic defects, but during the last decade epigenetic deregulation has been increasingly recognized as a hallmark of cancer. The advent of genome-scale analysis techniques, including the recently developed next-generation sequencing, has enabled an invaluable advance in the molecular mechanisms underlying tumor initiation, progression, and expansion. In this review we describe recent advances in the field of cancer epigenomics concerning DNA methylation, histone modifications, and miRNAs. In the near future, this information will be used to generate novel biomarkers of relevance to diagnosis, prognosis, and chemotherapeutic response.
多年来，癌症研究一直集中在遗传缺陷上，但在过去十年中，表观遗传失调已逐渐被视为癌症的一个标志。包括最近开发的下一代测序在内的基因组规模分析技术的出现，使得肿瘤起始、进展和扩张的分子机制取得了宝贵的进展。在这篇综述中，我们描述了癌症表观基因组学领域在 DNA 甲基化、组蛋白修饰和 miRNAs 方面的最新进展。在不久的将来，这些信息将用于生成与诊断、预后和化疗反应相关的新型生物标志物。
